Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Medivation Inc    MDVN   US58501N1019


SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

Medivation Inc : Medivation Announces Participation at Upcoming Investor Conferences

10/30/2013 | 04:34pm US/Eastern

SAN FRANCISCO, CA -- (Marketwired) -- 10/28/13 -- Medivation, Inc. (NASDAQ: MDVN) today announced that it will host a live teleconference with management to discuss third quarter 2013 financial results and provide a general business update on November 12, 2013 at 4:30 p.m. Eastern Time. A press release for the third quarter of 2013 will be released after markets close on November 12, 2013.

Interested parties may listen to the live teleconference by calling 877-303-2523 from the U.S. or +1-253-237-1755 internationally. Individuals may access the live audio webcast by visiting:

About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at

Patrick Machado
Chief Business & Financial Officer
(415) 829-4101

Anne Bowdidge
Sr. Director, Investor Relations
(650) 218-6900

Source: Medivation

News Provided by Acquire Media

distributed by
Recommend :
React to this article
Latest news on MEDIVATION INC
2d ago MEDIVATION : Appoints Patrick Machado to Board of Directors
5d ago MEDIVATION : Other Events (form 8-K)
04/08 Earnings Releases, Stock Price Movements, Company Milestone, Senior- level Ap..
04/03 MEDIVATION : Astellas Announces European Regulatory Submission For XTANDI® (enza..
04/01 MEDIVATION : Names Rick Bierly Chief Financial Officer
03/31 MEDIVATION : Change in Directors or Principal Officers (form 8-K)
03/31 MEDIVATION : Names Rick Bierly Chief Financial Officer
03/31 ASTELLAS PHARMA : NCCN Receives $2.2 Million in Research Funding from Astellas a..
03/25 ASTELLAS PHARMA : Announces Marketing Approval in Japan for XTANDI (enzalutamide..
03/24 MEDIVATION : Astellas Announces Marketing Approval in Japan for XTANDI® (enzalut..
Duration : Period :
Medivation Inc Technical Analysis Chart | MDVN | US58501N1019 | 4-Traders
Income Statement Evolution
Medivation Inc : Income Statement Evolution
More Financials
Dynamic quotes